The anti-doping agency's science lead gives a quick rundown of what competitors should know about peptides and where the prohibited line sits.
Recap by typeshit. Post by USADA on X.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Investors wanted a near-term plan but got 2030 targets instead, while CagriSema missed against Zepbound and Morgan Stanley downgraded the stock over the semaglutide patent cliff.
Tribeca Skin Center brings back its hot takes series with topical peptides in skincare as the subject and invites viewers to weigh in.
Loading…